Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms

David V. Erbe, Suyue Wang, Yan-Ling Zhang, Kimberly Harding, Leslie Kung, May Tam, Leslie Stolz, Yuzhe Xing, Sarah Furey, Ariful Qadri, Lori D. Klaman and James F. Tobin
Molecular Pharmacology January 2005, 67 (1) 69-77; DOI: https://doi.org/10.1124/mol.104.005553
David V. Erbe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suyue Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan-Ling Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Harding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Kung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May Tam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Stolz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuzhe Xing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Furey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariful Qadri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori D. Klaman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James F. Tobin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. In addition, treatment of rodents improved lipid profiles, with significantly lowered triglyceride and free fatty acid levels. These results suggested that this therapeutic activity might involve mechanisms in addition to PTP1b inhibition. In this study, we demonstrate that ertiprotafib activates peroxisome proliferator-activated receptor (PPAR)α and PPARγ at concentrations comparable with those of known agonists of these regulators. Furthermore, it is able to drive adipocyte differentiation of C3H10T1/2 cells, a hallmark of PPARγ activation. Livers from ertiprotafib-treated animals showed significant induction of acyl-CoA oxidase activity, probably caused by PPARα engagement in these animals. We also show that ertiprotafib inhibits PTP1b in vitro with nonclassic kinetics at concentrations above its EC50 for PPAR agonism. Thus, the complete mechanism of action for ertiprotafib and related compounds in vivo may involve multiple independent mechanisms, including (but not necessarily limited to) PTP1b inhibition and dual PPARα/PPARγ agonism. Ertiprotafib pharmacology and interpretation of clinical results must be seen in light of this complexity.

  • Received July 28, 2004.
  • Accepted October 7, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 67 (1)
Molecular Pharmacology
Vol. 67, Issue 1
1 Jan 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms

David V. Erbe, Suyue Wang, Yan-Ling Zhang, Kimberly Harding, Leslie Kung, May Tam, Leslie Stolz, Yuzhe Xing, Sarah Furey, Ariful Qadri, Lori D. Klaman and James F. Tobin
Molecular Pharmacology January 1, 2005, 67 (1) 69-77; DOI: https://doi.org/10.1124/mol.104.005553

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms

David V. Erbe, Suyue Wang, Yan-Ling Zhang, Kimberly Harding, Leslie Kung, May Tam, Leslie Stolz, Yuzhe Xing, Sarah Furey, Ariful Qadri, Lori D. Klaman and James F. Tobin
Molecular Pharmacology January 1, 2005, 67 (1) 69-77; DOI: https://doi.org/10.1124/mol.104.005553
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Action of Org 34167 on HCN channels
  • The effects of echinocystic acid on Kv7 channels
  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics